– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration –
– vRNA Immunotherapy Platform has the potential to address challenges associated with IV-administered RNA-based oncology therapeutics –
Read more at globenewswire.com